

CLINICAL CANCER MONOGRAPHS  
Volume 3

# Cancer of the Stomach

John W. L. Fielding, MD, FRCS

*Consultant Surgeon  
Queen Elizabeth Hospital  
Birmingham, England*


and

Jean Powell, BSc FIS

William H. Allum, MD, FRCS

John A. H. Waterhouse, MA, PhD, HonFRCM

Christopher C. McConkey, BSc



CLINICAL CANCER MONOGRAPHS

Volume 3

# Cancer of the Stomach

**John W. L. Fielding, MD, FRCS**

*Consultant Surgeon  
Queen Elizabeth Hospital  
Birmingham, England*

*and*

**Jean Powell, BSc, FIS**

**William H. Allum, MD, FRCS**

**John A. H. Waterhouse, MA, PhD, HonFFOM**

**Christopher C. McConkey, BSc**

*Regional Cancer Registry  
Queen Elizabeth Medical Centre  
Birmingham, England*

*with guest chapters by*

**M. Hockey, FRCS**

**J. Crocker, MA, MD, MRCPath**

**M  
STOCKTON**

©The Authors 1989

All rights reserved. No reproduction, copy or transmission of this publication may be made without written permission.

No paragraph of this publication may be reproduced, copied or transmitted save with written permission or in accordance with the provisions of the Copyright Act 1956 (as amended), or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 33-4 Alfred Place, London WC1E 7DP

Any person who does any unauthorised act in relation to this publication may be liable to criminal prosecution and civil claims for damages.

First published 1989

Published by  
THE MACMILLAN PRESS LTD  
Houndmills, Basingstoke, Hampshire RG21 2XS  
and London  
Companies and representatives  
throughout the world

Printed in Great Britain by  
Camelot Press Ltd, Southampton

British Library Cataloguing in Publication Data  
Cancer of the stomach.

1. Man. Stomach. Cancer

I. Fielding, John W. L. (John William Lewis) II.

Series

616.99'433

ISSN 0954-7495

ISBN 0-333-47264-0

Published in the United States and Canada by

Stockton Press

15 East 26th St, New York, NY 10010

ISBN 0-935859-80-2

Library of Congress Cataloging in Publication Data also available

M  
217792

# CANCER OF THE STOMACH



**Previous volumes in the series**

**CANCER OF THE STOMACH**

**Volume 1 *Cancer of the Oesophagus***

**Edited by H. R. Matthews *et al.* 1987. 184pp.**

**Volume 2 *Cancer of the Larynx***

**Edited by P. E. Robin *et al.* 1988. 238 pp.**





# Foreword

Gastric cancer is regarded by most clinicians as being a highly lethal malignancy. Five year survival figures in the UK, USA and Northern Europe rarely exceed 8% and yet there are some isolated centres that consistently report more favourable figures in each category of staged patients. Such observations may be due to case selection or conceivably due to improved treatment.

In order to avoid selection bias it is particularly valuable to report outcome from a stable, finite population base. The West Midlands Region's Cancer Registry is well equipped to provide exactly these data. The boundaries of the Region have remained stable and high quality data have been recorded since 1957. It is, indeed, timely that the observations from the Registry between 1957 and 1981 are now available. The report highlights the variations in operative mortality at a time when audit and CEPOD (Confidential Enquiry into Perioperative death) reports are being considered by our politicians, and when the whole question of specialisation is the subject of professional debate.

Subtle changes in the incidence of disease in relation to environmental factors has helped to shed some light on possible aetiological factors.

It is appropriate that this report should analyse in detail the results of surgical therapy within each stage of the disease. Surgery still remains the only reliable method of attempted cure. Improved staging methods are urgently needed, however, in selecting those patients in whom radical ablative gastrectomy and lymphadenectomy are justified. The authors are to be congratulated in producing a thoroughly informative work which helps to formulate rational treatment policies.

Sadly, unless clinicians strive to achieve earlier diagnosis of disease, much of our surgical efforts will be relatively fruitless. This monograph indirectly makes the case for screening dyspeptic patients and establishing specialist centres for training within which treatment modalities can be comprehensively compared.

M R B Keighley MS FRCS  
Barling Professor of Surgery

# Acknowledgements

## The Cancer Research Campaign

All the analytical work, and preparation of tables, graphs and diagrams by the small Monograph Research Team, has been wholly supported by the Cancer Research Campaign.

## Regional Cancer Registry

The original data on which this series is based is entirely from the Birmingham and West Midlands Regional Cancer Registry.

We thank all those who - over many years - have given so generously of their time and expertise to ensure the completeness and accuracy of the data in the Registry. These include:

### From the Registry:

All the staff both past and present.

### From hospitals:

Consultant clinicians and pathologists  
Administrators  
Junior medical staff  
Laboratory technicians  
Medical records staff  
Medical secretaries

### Throughout the Region:

Coroners  
General Practitioners  
Staff of Family Practitioner Committees

### Nationally:

The staffs of the Cancer Registration Sections of:  
The Office of Population Censuses and Surveys.  
The National Health Service Central Register.

### From the University of Birmingham:

The staff of the Computer Centre.

All the illustrations were produced using Tellagrap on the University's Honeywell Multics Computer.

### From the Monograph Team:

Mrs. Vanessa Chadderton for her artistic and accurate preparation of the figures and the final camera ready layout

Mrs. Judy Connor and Mrs. Margaret Williams for their painstaking preparation of the text and tables.

# Contents

Foreword, by Professor M.R.B. Keighley	xiii
Acknowledgements	xiv
<b>1 Introduction and Methods</b>	<b>1</b>
1.1 Introduction	1
1.2 Inclusion criteria	3
1.3 Data base	3
1.4 Validation procedures	3
1.5 Survival data	4
1.6 Statistical methods	5
1.7 Population	6
Figure 1.1 1961 and 1981 census population pyramid	8
Table 1.7.1 Comparison of social factors	9
Table 1.7.2 Population densities	10
Table 1.7.3 Populations used for the different time periods	11
1.8 General arrangement	11
<b>2 Epidemiology: Demographic Aspects</b>	<b>12</b>
Summary	12
Table 2.1 Number per annum by sex	13
Figure 2.1 Number per annum by sex	14
Table 2.2.1 Incidence rates by quinquennium and sex	14
Table 2.2.2 Sex ratio of incidence rates by quinquennium	14
Figure 2.2 Incidence rates by quinquennium and sex	15
Table 2.3 Numbers and incidence rates by age and sex	16
Figure 2.3 Incidence rates by age and sex	17
Table 2.4.1 Numbers by age and quinquennium, males	18
Table 2.4.2 Numbers by age and quinquennium, females	19



Table 2.5.1	Incidence rates by age and quinquennium, males
Table 2.5.2	Incidence rates by age and quinquennium, females
Table 2.5.3	Incidence rates by age, decennium and sex
Figure 2.5	Incidence rates by age, decennium and sex
Table 2.6	Age distribution by decennium and sex
Figure 2.6	Age distribution by decennium and sex
Table 2.7	Incidence by birth cohort and sex
Figure 2.7.1	Incidence by birth cohort, males
Figure 2.7.2	Incidence by birth cohort, females
Table 2.8.1	Incidence by quinquennium and subsite, males
Table 2.8.2	Incidence by quinquennium and subsite, females
Figure 2.8	Incidence by quinquennium, subsite and sex
Table 2.9.1	Incidence by subsite, males
Table 2.9.2	Incidence by subsite, females
Figure 2.9	Incidence by age, subsite and sex
Table 2.10	Social class
Table 2.11.1	Occupation, males
Table 2.11.2	Occupation by subsite, males
Table 2.12.1	Numbers and SRR by district and sex
Table 2.12.2	SRR by district related to social class
Figure 2.12.2	SRR by district related to social class
Figure 2.12.3	Map of West Midlands Region
Table 2.13	Incidence in different countries

### 3 Histology

	Summary
Table 3.1.1	Histological categories
Table 3.1.2	Proportions with no histology by quinquennium
Table 3.2	Numbers and distribution with specified histology
Table 3.3	Histological type by site
Table 3.4.1	Annual survival by histological verification
Figure 3.4.1	Annual survival by histological verification
Table 3.4.2	5 year survival by stage and histological verification
Table 3.5	Resected cases: annual survival by histology
Figure 3.5	Resected cases: annual survival by histology
Table 3.6	Annual survival by differentiation
	Resected cases
Table 3.7	Annual survival by differentiation
Figure 3.7	Annual survival by differentiation
Table 3.8	Distribution by stage and differentiation
Figure 3.8	Distribution by stage and differentiation
Table 3.9	5 year survival by stage and differentiation
Figure 3.9	Annual survival by stage and differentiation

**4 Presentation and Investigations**

	<b>Summary</b>	<b>54</b>
Table 4.1	<b>First symptom: Proportions specified</b>	<b>55</b>
	<b>Duration of symptoms</b>	
Table 4.2	Distribution	56
Table 4.3	Distribution by quinquennium	57
Figure 4.3	Distribution by quinquennium	57
Table 4.4	Distribution by age	58
Figure 4.4	Distribution by age	59
Table 4.5	Known duration by stage	60
Table 4.6	Distribution by stage	60
Figure 4.6	Distribution by stage	61
Table 4.7	Median by stage and subsite	62
Figure 4.7	Median by stage and subsite	62
Table 4.8	Annual survival	63
Figure 4.8	1 and 5 year survival	63
Table 4.9.1	1 year survival by stage	64
Table 4.9.2	5 year survival by stage	64
Figure 4.9	5 year survival by stage	65
	<b>Type of first symptom</b>	
Table 4.10	Number by type	66
Figure 4.10	Distribution by type	67
Figure 4.11	Distribution by site	68
Table 4.12	Median duration by type	69
Figure 4.12	Median duration by type	69
Table 4.13.1	Numbers by stage and site	70
Table 4.13.2	Symptoms by stage and site	71
Table 4.14	Median duration by type and stage	72
	<b>Methods of diagnosis</b>	
Table 4.15	Numbers per annum	73
Figure 4.15	Numbers per annum	73
Table 4.16	Distribution by quinquennium	74

**5 Overall Treatment and Survival**

	<b>Summary</b>	<b>75</b>
Table 5.1	Distribution by site and quinquennium	77
Figure 5.1	Distribution by site and quinquennium	77
Table 5.2	Distribution by stage and quinquennium	78
Figure 5.2	Distribution by stage and quinquennium	79
Table 5.3	Distribution by type of treatment	80
Figure 5.3	Distribution by type of treatment	81
Table 5.4	Distribution by treatment within site	82
Figure 5.4.1	Distribution by treatment within site	83
Figure 5.4.2	Unspecified site: treatment distribution	84
Figure 5.5	Distribution by treatment and age	84
Table 5.5	Distribution by treatment and age	85

Table 5.6	Distribution by treatment and quinquennium	86
Figure 5.6	Distribution by treatment and quinquennium	87
Table 5.7	Annual rates, crude and age adjusted	88
Figure 5.7	Annual rates, crude and age adjusted	89
Table 5.8	Annual rates by quinquennium	90
Figure 5.8	Annual rates by decennium	91
Table 5.9	5 year rates, crude and age adjusted by age	92
Figure 5.9	5 year rates, crude and age adjusted by age	93
Table 5.10	5 year rates by quinquennium and site	93
Table 5.11	Annual rates by stage	94
Figure 5.11	Annual rates by stage	95
Table 5.12	5 year rates by stage and decade	96
Figure 5.12	Curatively resected: annual rates by decade	96
Table 5.13	Curatively resected: 5 year rates by stage and decade	97
Table 5.14	5 year rates, crude and age adjusted by treatment	98
Table 5.15	5 year rates by treatment and decade	99
Figure 5.15	Annual rates by treatment and decade	99
Table 5.16	One month mortality by treatment and decade	100
Table 5.17	Curatively resected: 5 year rates by type of gastrectomy and decade	101
Table 5.18	Deaths within one month by type of gastrectomy and site	102
<b>6 Stages I - IVA</b>		<b>103</b>
	Summary	104
Table 6.1	Distribution and 5 year rates by stage	105
	<b>Stage I by type of gastrectomy</b>	
Table 6.2.1	Annual rates, crude and age adjusted	106
Figure 6.2.1	Annual rates	107
Table 6.2.2	Distribution and survival by sex	107
Table 6.2.3	Distribution and 1 month mortality by age	108
Table 6.2.4	5 year rates by age	109
Table 6.2.5	Distribution and survival by duration of symptoms	110
Table 6.2.6	Distribution and survival by site	111
	<b>Stage II by type of gastrectomy</b>	<b>112</b>
Table 6.3.1	Annual rates, crude and age adjusted	112
Figure 6.3.1	Annual rates	112
Table 6.3.2	Distribution and survival by sex	113
Figure 6.3.2	Annual rates by sex	113
Table 6.3.3	Distribution and 1 month mortality by age	114
Figure 6.3.3	Distribution and 1 month mortality by age	115
Table 6.3.4	5 year rates by age	116
Figure 6.3.4	5 year rates by age	117

Table 6.3.5	Distribution and survival by duration of symptoms	118
Figure 6.3.5	5 year rates by duration of symptoms	119
Table 6.3.6	Distribution and survival by site	120
Figure 6.3.6	1 month mortality and annual rates by site	121
	<b>Stage III by type of gastrectomy</b>	
Table 6.4.1	Annual rates, crude and age adjusted	122
Figure 6.4.1	Annual rates	122
Table 6.4.2	Distribution and survival by sex	123
Figure 6.4.2	Annual rates by sex	123
Table 6.4.3	Distribution and 1 month mortality by age	124
Figure 6.4.3	Distribution and 1 month mortality by age	125
Table 6.4.4	5 year rates by age	126
Figure 6.4.4	5 year rates by age	127
Table 6.4.5	Distribution and survival by duration of symptoms	128
Figure 6.4.5	5 year rates by duration of symptoms	129
Table 6.4.6	Distribution and survival by site	130
Figure 6.4.6	1 month mortality and annual rates by site	131
	<b>Stage not known by type of gastrectomy</b>	
Table 6.5.1	Annual rates, crude and age adjusted	132
Figure 6.5.1	Annual rates	133
Table 6.5.2	Distribution and survival by sex	134
Figure 6.5.2	Annual rates by sex	135
Table 6.5.3	Distribution and 1 month mortality by age	136
Figure 6.5.3	Distribution and 1 month mortality by age	137
Table 6.5.4	5 year rates by age	138
Figure 6.5.4	5 year rates by age	139
Table 6.5.5	Distribution and survival by duration of symptoms	140
Figure 6.5.5	5 year rates by duration of symptoms	141
Table 6.5.6	Distribution and survival by site	142
Figure 6.5.6	1 month mortality and annual rates by site	143
	<b>Stage IVA by type of gastrectomy</b>	
Table 6.6.1	Annual rates, crude and age adjusted	144
Figure 6.6.1	Annual rates	145
Table 6.6.2	Distribution and survival by sex	146
Figure 6.6.2	Annual rates by sex	147
Table 6.6.3	Distribution and 1 month mortality by age	148
Figure 6.6.3	Distribution and 1 month mortality by age	149
Table 6.6.4	5 year rates by age	150
Figure 6.6.4	5 year rates by age	151
Table 6.6.5	Distribution and survival by duration of symptoms	152
Figure 6.6.5	5 year rates by duration of symptoms	153
Table 6.6.6	Distribution and survival by site	154
Figure 6.6.6	1 month mortality and annual rates by site	155

<b>7 Unresected Cases</b>		<b>156</b>
	<b>Summary</b>	<b>156</b>
Table 7.1	Type of treatment and 1 month mortality	157
	<b>Reasons for no resection</b>	
Table 7.2	Distribution	158
Table 7.3	Effect of age	158
Figure 7.3	Effect of age	159
Table 7.4	Sex, age and duration of symptoms	160
Table 7.5	Distribution by site	160
Table 7.6	Type of treatment	161
Table 7.7	Type of treatment by sex and mean age	162
Table 7.8	Type of treatment by age	162
Figure 7.8	Type of treatment by age	163
Table 7.9.1	Type of treatment by site	164
Table 7.9.2	1 month mortality by treatment and site	165
Table 7.10	Annual rates, crude and age adjusted	165
Table 7.11	Annual rates by reason for no resection	166
Table 7.12	Annual rates by type of treatment	166
Figure 7.12	Age adjusted survival rates by type of treatment	167
Table 7.13	6 month and 2 year rates by treatment and age	168
Table 7.14	6 month and 2 year rates by treatment and duration of symptoms	169
<b>8 Prognostic Factors</b>		<b>170</b>
	<b>Summary</b>	<b>171</b>
Table 8.1	5 year rates, crude and age adjusted by stage	172
Figure 8.1.1	Distribution by stage	173
Figure 8.1.2	Annual rates by stage	173
Table 8.2	Annual rates, crude and age adjusted by sex	174
Figure 8.2	Annual rates by sex	175
Table 8.3	Effect of age	175
Figure 8.3.1	Effect of age	176
Figure 8.3.2	5 year rates by age and stage	177
Figure 8.3.3	5 year rates by age and stage excluding deaths within 1 month	177
Table 8.4	5 year rates by duration of symptoms	178
Figure 8.4.1	Duration of symptoms	178
Figure 8.4.2	1 and 5 year rates by duration of symptoms	179
Figure 8.4.3	5 year rates by duration of symptoms and stage	179
Table 8.5	Site distribution for all cases and curatively resected	181
Figure 8.5	Site distribution	181



# Contents

xi

Table 8.6	Curatively resected: 5 year rates by site	182
Figure 8.6.1	Curatively resected: annual rates by site	182
Figure 8.6.2	Curatively resected: annual rates by stage and site	183
	<b>Type of curative gastrectomy</b>	
Figure 8.7	Annual rates	184
Table 8.8.1	5 year rates by stage	185
Table 8.8.2	5 year rates by stage excluding deaths within 1 month	185
Figure 8.8.1	Annual rates by stage	186
Figure 8.8.2	Annual rates by stage excluding deaths within 1 month	187
Table 8.9	Effect of frequency of performance of gastrectomies on operative mortality and survival	188
<b>9 Unusual Tumours</b>		190
	<b>Summary</b>	190
Table 9.1	Numbers by histological type	191
Table 9.2	Clinical details of carcinoid, squamous cell carcinoma variants or melanoma	192
Table 9.3	Sarcoma: numbers by histology and sex	201
Table 9.4	Clinical details of sarcoma other than leiomyosarcoma	202
	<b>Leiomyosarcoma</b>	
Table 9.5	Numbers by quinquennium and sex	204
Figure 9.5	Numbers per annum by sex	204
Table 9.6	Numbers and incidence by age and sex	205
Figure 9.6	Incidence by age and sex	205
Table 9.7	Age distribution by sex	206
Figure 9.7	Age distribution by sex	206
Table 9.8	Annual rates by sex	207
Figure 9.8	Annual rates by sex	207
Table 9.9	Annual rates by treatment and sex	208
Figure 9.9	Annual rates by treatment	208
Table 9.10	Annual rates by treatment and sex excluding deaths within 1 month	209
Figure 9.10	Annual rates by treatment excluding deaths within one month	209
<b>10 Lymphoma, by M.S. Hockey and J. Crocker</b>		210
	<b>Summary</b>	211
Table 10.1	Number per annum	212
Figure 10.1.1	Number per annum by sex	213
Figure 10.1.2	Comparison with gastric carcinoma	213

## Contents

Table 10.2	Numbers and incidence by age and sex	214
Figure 10.2.1	Distribution by age and sex	215
Figure 10.2.2	Incidence by age and sex	215
Table 10.3	Histological classification	216
Table 10.4	Numbers by quinquennium and sex	217
Table 10.5	Numbers by age and histology	218
Figure 10.5	Distribution by age and grade	218
Table 10.6	Numbers by stage and review status	219
Table 10.7	Annual rates, crude and age adjusted by sex	220
Figure 10.7	Annual rates by sex	220
Table 10.8	5 year rates by histological type	222
Table 10.9	Annual rates, crude and age adjusted by histological grade	223
Figure 10.9	Annual rates by histological grade	223
Table 10.10	5 year rates, crude and age adjusted by age	224
Figure 10.10	5 year rates by age	224
Table 10.11	Annual rates by stage	225
Figure 10.11	Annual rates by stage	226
Table 10.12	5 year rates, crude and age adjusted by treatment	227
Table 10.13	Curatively treated: 5 year rates by treatment and stage	228
Figure 10.13	Curatively treated: annual rates by treatment and stage	229
Table 10.14	5 year rates, crude and age adjusted by treatment, nodal involvement and review status	230
<b>Appendix 1 Standardised Rates</b>		231
A1.1	Standardised incidence rates	231
A1.2	Survival rates	234
A1.3	Age adjustment of survival rates	234
A1.4	Numerical illustrations	236
<b>Appendix 2 Census and inter-censal populations</b>		239
<b>Appendix 3 Immunohistochemistry of gastric lymphoma by J. Crocker</b>		241
A3.1	Antibodies of value in diagnosis of gastric lymphomas	242
A3.2	Suggested sequential scheme	243
A3.3	Results: Gastric lymphomas 1977-1981	244
<b>References</b>		246

# Introduction and Methods

## 1.1 Introduction

It is now just over 100 years since Theodore Billroth successfully undertook the first gastrectomy for a carcinoma of the stomach. The patient was node positive and succumbed within a short time to the disease. Billroth's major achievement was that the patient survived surgery. Many of the advances since that time have come in safer surgical and anaesthetic techniques, and gastrectomy is now a safer procedure. Whilst in the Western World, particularly in the United States of America, there has been a significant decrease in the incidence of this lesion, world-wide it still remains the most common cause of death from malignant disease and there are strong indications that the incidence of lesions of the cardia are increasing.

Internationally, there are now apparent differences in the results of the management of this neoplasm. In Japan particular attention has been given to the diagnosis and treatment of this disease, with improved results. These improvements have been based on treating large numbers of patients and are worthy of comparison with the results being achieved elsewhere. Certainly in the Western World there has been little change in the reported results of survival in this condition. Well-known features are common to all countries of the world. It is a tumour of males; it occurs more frequently in the lower social classes; there are regional variations within a country, in addition to the well-documented international variations. Classically, it is found more commonly in the antrum of the stomach though there is evidence coming from many centres that lesions of the cardia are increasing in frequency. It is clearly established that clinicopathological stage is the most important prognostic feature and that lesions confined to the

gastric wall, particularly the mucosa and sub-mucosa are associated with a good prognosis. The results by stage of disease are consistent between most countries. There is, however, one exception, that is in Japan where the results reported for each stage of disease are significantly better than those seen in other series. These may indicate either an inherent difference in the disease seen in Japan, or a different therapeutic strategy perhaps related to the physical condition of patients (at time of presentation). Certainly in Japan there are high laparotomy rates and the surgery is more aggressive and associated with a low operative mortality. These features may be important in explaining survival differences.

This Monograph studies the management of gastric cancer within a region of Britain over a 25 year period. This large collection of cases has explored many of the features alluded to in the preceding paragraph. A particular effort was made to stage these cases and this has confirmed the importance of this as a prognostic factor. This study highlights other features which may be appropriate in considering the future management of this condition. There is an unacceptably high operative mortality: particularly following total gastrectomy in potentially curable disease. This can be related to the number of cases being treated each year. Even allowing for this, the operative mortality rates do not match those reported from Centres which are more specialised and have developed greater expertise. There is clearly an indication for the treatment of patients with gastric cancer in specialised units. However, an interesting development of the last decade has not only been an improvement in laparotomy rates, but also an improved survival following resection of the disease, perhaps suggesting the development of a specialised interest.

Whilst this volume has concentrated mainly on the common adenocarcinoma of the stomach, it also provides the largest collection of cases of the uncommon lesions of the stomach. This is an invaluable basis for comparative results in these lesions. The improved prognosis of lymphomas over adenocarcinoma is clear. It is in this tumour that significant results in treatment may be apparent over the next decade. This study already highlights the possibility of chemotherapy playing a significant role in the management of lymphomas.

The study about to be described provides one of the largest and most thorough, and with 99.88% follow-up, must be one of the most complete. Indeed, as the primary function of a registry is to include all cases, the results reported here satisfy many of the current needs for audit. They also form the base line on which subsequent data must be evaluated. It is hoped that by staging patients it will be possible for individuals to compare their results with similar disease and provide a basis for retrospective or prospective comparisons.